IL22 and psoriasis: CD8+ TRM in the skin of patients suffering from psoriasis express the IL23 receptor, and, therefore, are able to produce pro-inflammatory interleukin (IL)-17 and IL-22 in the psoriatic skin, even for many months after remission [4,9].